Compare AbbVie Inc (ABBV) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? AbbVie Inc trades at $253.63 (market cap $449.91B), while Global X NASDAQ 100 Covered Call ETF trades at $18.05. The key difference: AbbVie Inc pays a 2.72% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Global X NASDAQ 100 Covered Call ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | QYLD | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $261.07 | $18.52 |
52-Week Low | $184.85 | $16.46 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
QYLD trades at $18.34, up 1.38% with a bullish technical signal driven by moving averages, though oscillators remain neutral. The ETF's covered-call strategy generates high monthly dividends, with recent payouts of $0.19 and $0.18, but long-term performance has lagged the Nasdaq-100's growth. News highlights concerns over NAV erosion despite the 12% yield.
Outlook: High income appeals to retirees, but capital appreciation is limited by the covered-call structure. Risks include underperformance in bull markets and concentration in tech. Investors prioritize yield over growth, yet must monitor erosion risks highlighted by financial media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
